DDDR-07. TARGETING THE CIRCADIAN CLOCK WITH SMALL MOLECULE COMPOUNDS RESULTS IN ANTI-TUMOR EFFECTS SPECIFICALLY IN GLIOBLASTOMA STEM CELLS

Abstract

Abstract Glioblastoma multiforme (GBM) is the most common primary brain tumor, with an average survival time of less than one year following diagnosis. Treatment success remains challenging despite aggressive, multimodal current standard-of-care consisting of maximal surgical resection followed by concurrent temozolomide (TMZ) chemotherapy and radiation. The presence of GBM stem cells (GSCs) is thought to make treatment exceptionally difficult as they are highly invasive, resistant to chemoradiation, promote angiogenesis, support an immune suppressive environment, and can recapitulate the primary tumor following surgical resection. We have reported that GSCs, however, are dependent on core circadian clock proteins, Brain and Muscle ARNTL-Like 1 (BMAL1) and Circadian Locomoter Output Cycles Protein Kaput (CLOCK), which is not observed in differentiated GBM cells or normal neuronal stem cells. In this study, we explore the anti-GSC effects of multiple families of novel small molecule circadian clock compounds that either lower BMAL1 transcription (REV-ERB agonists) or inhibit BMAL1::CLOCK heterodimer transcriptional activity (Cryptochrome (CRY) stabilizers or Casein Kinase (CK) 1/2 inhibitors). Here we report that compared to compared to non-cancerous cells, U2OS human osteosarcoma cells, and differentiated GSCs (DGCs), GSCs display increased sensitivity to clock compounds at single agent and combinatory doses of clock compounds. Additionally, clock compounds are significantly more effective in targeting GSCs than TMZ and combinations of clock compounds with TMZ can lower TMZ IC50 value in different GBM cell lines and types. Application of the CRY stabilizer SHP1705 in GBM PDX patient derived xenograft (PDX) models resulted in decreased tumor growth rate and increased survival time compared to vehicle control. These results highlight the therapeutic potential of circadian clock compounds as single agents, in combinations and as adjuvants to existing therapies by specifically targeting the GSC population in GBM.